Featured Research

from universities, journals, and other organizations

Low BMI is a risk factor for CVD in hypertensive patients with diabetes

Date:
September 3, 2013
Source:
European Society of Cardiology
Summary:
The findings of this study provide evidence for an obesity paradox in hypertensive patients with glucose intolerance.

Low BMI is a risk factor for CVD in hypertensive patients with diabetes, according to research presented at the ESC Congress today by Dr Takanori Nagahiro from Japan. The findings provide evidence for an obesity paradox in hypertensive patients with glucose intolerance.

Related Articles


Dr Nagahiro said: "Obesity is a risk factor for cardiovascular disease (CVD) but several studies have reported that low body mass index (BMI, kg/m2) was associated with worse cardiovascular outcome compared to middle or higher BMI. This strange phenomenon is called the 'obesity paradox' and has been described in patients with stroke, heart failure, coronary artery disease and renal disease."

He added: "The obesity paradox was reported in diabetic patients in 2012. Adults who were normal weight at the time of incident diabetes had higher mortality than adults who were overweight or obese.1 However, the relationship between obesity and cardiovascular events in patients with diabetes and hypertension is unknown." The current study assessed the relationship between BMI and cardiovascular events in patients with hypertension and glucose intolerance. The researchers used data from the Nagoya Heart Study, a randomised trial comparing the efficacies of valsartan and amlodipine among 1,105 hypertensive patients with glucose intolerance in Japan. Patients were enrolled from October 2004 to January 2009 and the median follow-up was 3.2 years. The CVD endpoint was a composite of acute myocardial infarction, stroke, admission due to heart failure, coronary revascularization, or sudden cardiac death.

Patients were classified2 into four groups according to their baseline BMI: <23kg/m2 (n=283), 23 to 24.99kg/m2 (n=290), 25.00 to 27.49kg/m2 (n=277), and ≥27.50kg/m2 (n=255). Stratified analyses were performed according to these groups with the lowest BMI category as reference.

The primary endpoint occurred in 42 patients (14.8%, 4.6/100 patient-years) in the lowest BMI category (the reference group), 24 patients (8.3%, 2.3/100 patient-years) in the BMI 23.00 to 24.99kg/m2 group (hazard ratio [HR] =0.48), 27 patients (9.7%, 2.8/100 patient-years) in the BMI 25.00 to 27.49kg/m2 group (HR=0.57), and 13 patients (5.1%, 1.5/100 patient-years) in the highest BMI category (HR=0.32).

Dr Nagahiro said: "As BMI increased, CVD risk decreased among Japanese hypertensive patients with glucose intolerance. After adjustment for age, gender and smoking status, the lowest BMI group showed the highest CVD incidence and the highest BMI group had the lowest CVD incidence. CVD risk in the highest BMI group was less than one-third that of the lowest BMI group." The Kaplan-Meier curve shows the proportion of patients who reached the primary endpoint over time. The maximum follow-up period was 2,126 days (5.8 years). Dr Nagahiro said: "Our study shows that there is an obesity paradox in hypertensive patients with glucose intolerance. This may be because of the severity of diabetes mellitus in the lowest BMI group. Baseline HbA1c and disease duration is similar to other groups however the percentage of insulin therapy is higher than other groups. This background indicates that the severity of diabetes mellitus is different. The two middle BMI groups had similar CVD risk, probably because mild obesity needs more time to exert an adverse effect on the cardiovascular system."

He concluded: "Hypertensive patients with glucose intolerance and a high BMI should lose weight and restore their BMI to normal range. The results of our study did not refute the fact that severe obesity is a CVD risk factor."


Story Source:

The above story is based on materials provided by European Society of Cardiology. Note: Materials may be edited for content and length.


Cite This Page:

European Society of Cardiology. "Low BMI is a risk factor for CVD in hypertensive patients with diabetes." ScienceDaily. ScienceDaily, 3 September 2013. <www.sciencedaily.com/releases/2013/09/130903091534.htm>.
European Society of Cardiology. (2013, September 3). Low BMI is a risk factor for CVD in hypertensive patients with diabetes. ScienceDaily. Retrieved March 6, 2015 from www.sciencedaily.com/releases/2013/09/130903091534.htm
European Society of Cardiology. "Low BMI is a risk factor for CVD in hypertensive patients with diabetes." ScienceDaily. www.sciencedaily.com/releases/2013/09/130903091534.htm (accessed March 6, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Friday, March 6, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Bupa Eyes India Healthcare Opportunities

Bupa Eyes India Healthcare Opportunities

Reuters - Business Video Online (Mar. 5, 2015) Bupa is hoping to expand in India&apos;s fast-growing health insurance market, once a rule change on foreign investment is implemented. The British private healthcare group&apos;s CEO tells Grace Pascoe why it&apos;s so keen on the new opportunity. Video provided by Reuters
Powered by NewsLook.com
Liberia Releases Last Ebola Patient, But Threat Remains

Liberia Releases Last Ebola Patient, But Threat Remains

Newsy (Mar. 5, 2015) Liberia&apos;s last Ebola patient has been released, and the country hasn&apos;t recorded a new case in a week. However, fears of another outbreak still exist. Video provided by Newsy
Powered by NewsLook.com
Doctor in Your Pocket Is Getting Smarter

Doctor in Your Pocket Is Getting Smarter

Reuters - Business Video Online (Mar. 5, 2015) Mobile apps are turning smartphones into a personal doctors, with users able to measure heart rate, blood pressure and even blood sugar. But will it change our behaviour? Ivor Bennett reports from the Mobile World Congress in Barcelona. Video provided by Reuters
Powered by NewsLook.com
AbbVie Inks $21B Deal To Buy Cancer Drugmaker Pharmacyclics

AbbVie Inks $21B Deal To Buy Cancer Drugmaker Pharmacyclics

Newsy (Mar. 5, 2015) AbbVie announced Wednesday it will buy cancer drugmaker Pharmacyclics in a $21 billion deal. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins